1. COVID-19: Drug Targets and Potential Treatments
- Author
-
Gil, Carmen, Ginex, Tiziana, Maestro, Inés, Nozal, Vanesa, Barrado-Gil, Lucía, Cuesta-Geijo, Miguel Ángel, Urquiza, Jesús, Ramírez, David, Alonso, Covadonga, Campillo, Nuria E., Martinez, Ana, Consejo Superior de Investigaciones Científicas (España), Fundación 'la Caixa', Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Comisión Nacional de Investigación Científica y Tecnológica (Chile), Fondo Nacional de Desarrollo Científico y Tecnológico (Chile), European Commission, Gil, Carmen [0000-0002-3882-6081], Ginex, Tiziana [0000-0002-5739-8713], Maestro, Inés [0000-0002-5026-5803], Nozal, V. [0000-0001-5260-5683], Barrado-Gil, Lucía [0000-0002-1053-2997], Cuesta-Geijo, Miguel Ángel [0000-0003-4694-1968], Urquiza, Jesús [0000-0002-7870-4580], Ramírez, David [0000-0003-0002-1189], Alonso, Covandoga [0000-0002-0862-6177], Campillo, Nuria E. [0000-0002-9948-2665], Martínez, Ana [0000-0002-2707-8110], Gil, Carmen, Ginex, Tiziana, Maestro, Inés, Nozal, V., Barrado-Gil, Lucía, Cuesta-Geijo, Miguel Ángel, Urquiza, Jesús, Ramírez, David, Alonso, Covandoga, Campillo, Nuria E., and Martínez, Ana
- Subjects
Drug ,Drug targets ,viruses ,media_common.quotation_subject ,Druggability ,Disease ,medicine.disease_cause ,Bioinformatics ,Antiviral Agents ,01 natural sciences ,03 medical and health sciences ,Drug Discovery ,Pandemic ,medicine ,Animals ,Humans ,Amino Acid Sequence ,Enzyme Inhibitors ,030304 developmental biology ,Coronavirus ,media_common ,0303 health sciences ,Innate immune system ,SARS-CoV-2 ,Drug discovery ,Chemistry ,Drug Repositioning ,COVID-19 ,virus diseases ,Antivirals ,Immunity, Innate ,COVID-19 Drug Treatment ,0104 chemical sciences ,3. Good health ,010404 medicinal & biomolecular chemistry ,Drug repositioning ,Perspective ,Molecular Medicine - Abstract
92 p.-22 fig.-1 tab.-1 graph. abst., Currently, we are immersed in a pandemic caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which severely threatens public health worldwide. Until now, no drug or vaccine has been approved to treat the severe disease caused by this coronavirus, COVID-19. We will focus on the main virus-based and host-based targets that can guide medicinal chemistry efforts to discover new drugs for this devastating disease. In principle, all CoVs enzymes and proteins involved in viral replication and the control of host cellular machineries are potentially druggable targets in the search for therapeutic options for SARS-CoV-2. This perspective provides an overview of the main targets from a structural point of view, together with reported therapeutic compounds with activity against SARS-CoV-2 and/or other CoVs. Also, the role of innate immune response to coronavirus infection and the related therapeutic options will be presented., Funding from CSIC (201980E024 and 202020E103) is acknowledged. This research was partially supported through "la Caixa" Banking Foundation (HR18-00469), Instituto de Salud Carlos III (ISCIII-COV20/01007), Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00), CONICYT-PCI (REDES190074 to D. R. and A. M.) and FONDECYT (11180604 to D.R.). I. M. was funded by H2020-MSCA-ITN-2017 (grant no. 765912), V. N. holds a pre-doctoral FPU grant (FPU16/04466) and J. U. was financed by FPI-SGIT2018-04.
- Published
- 2020